Company Profile for NOXXON Pharma AG.NOXXON Pharma AG is a drug discovery and development company with a validated val·i·date tr.v. val·i·dat·ed, val·i·dat·ing, val·i·dates 1. To declare or make legally valid. 2. To mark with an indication of official sanction. 3. proprietary technology platform to produce novel therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . NOXXON's drugs, called Spiegelmers, are highly specific, biostable, next generation aptamers. NOXXON's business strategy is based on a three-branch approach: A) Using its proprietary Spiegelmer technology, the Company builds its own pipeline of therapeutics for angiogenic angiogenic /an·gio·gen·ic/ (-jen´ik) 1. pertaining to angiogenesis. 2. of vascular origin. angiogenic adjective Relating to angiogenesis disorders and inflammatory diseases Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; . B) NOXXON collaborates with pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. to create Spiegelmer therapeutics against targets of the partner's choosing. C) NOXXON generates products for out-licensing at different research and development stages. Collaborative partnerships and out-licensing provide upfront and milestone payments, and generate downstream revenue through product royalties. This approach maximizes the return on the Company's know-how and technical capability. By offering drug discovery services See service discovery. to partners in addition to developing its own product pipeline, NOXXON builds significant corporate value and reduces the financial risk as it moves forward. NOXXON will enter clinical trials in the 1st half of 2008 in two different disease indications. The Company intends to finance the initial stages of clinical trials through phase II with its own resources.
Company: NOXXON Pharma AG
Headquarters Address: Max-Dohrn-Str. 8-10
Berlin 10589
Germany
Main Telephone: +49 30 726 247 0
Type of Organization: Private
Industry: Health: Biotechnology
Key Executives: CEO & CSO: Sven Klussmann
CDO: Norma Selve
Executive Assistant
Contact: Esther Brimacombe
Phone: +49 30 726 247 100
Email: ebrimacombe@noxxon.net
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion